Logo

    clostridioidesdifficile

    Explore "clostridioidesdifficile" with insightful episodes like "#25 Exploring Antibiotic Resistance & Stewardship in New York State with Dr. Danielle Durant", "MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert" and "C-Diff Can Be Deadly" from podcasts like ""American Journal of Infection Control: Science Into Practice", "MPR Weekly Dose" and "PodcastDX"" and more!

    Episodes (3)

    #25 Exploring Antibiotic Resistance & Stewardship in New York State with Dr. Danielle Durant

    #25 Exploring Antibiotic Resistance & Stewardship in New York State with Dr. Danielle Durant

    Are you an Infection Preventionist looking to learn more about the Healthcare Association of New York's State Antibiotic Stewardship Collaborative in 2015? Join us as we talk to Dr. Danielle Durant about her research and paper evaluation of the Collaborative. Dr. Durant provides us with an extensive background on HANES and the AUR Module of NHSN, revealing how the Collaborative's two aims were to prepare hospitals for mandated usage reporting and develop a robust program to help them prevent MDROs.

    With special guest:

    Dr. Danielle Durant

    MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert

    MPR Weekly Dose 157 — Akorn Pharmaceutical Recalls; First Oral Fecal Microbiota Tx; ALS Treatment Approved; Basal-Only Insulin Delivery for T2D; Eyedrop Safety Alert

    Large recall of drugs due to company shutdown; First orally administered fecal microbiota treatment given green light; Treatment approved for certain ALS patients; Type 2 diabetes insulin delivery system; FDA issue safety alert concerning eyedrops.

    C-Diff Can Be Deadly

    C-Diff Can Be Deadly

    This week we had the honor to speak with Christian John Lillis. Christian is executive director of the Peggy Lillis Foundation for C. diff Education & Advocacy (PLF), co-founded with his brother, Liam, following the death of their mother from a Clostridioides difficile (C. diff) infection in April 2010. PLF envisions a world where C. diff is rare, treatable, and survivable. In pursuit of its vision, PLF is building a nationwide C. diff awareness movement to educate the public, empower advocates, and shape policy.

    Peggy Lillis (deceased) Christian Lillis and Liam Lillis

    C. difficile or C-Diff is short for the name of the germ that causes the infection: Clostridioides difficile.  C. difficile can affect anyone. The risks are greater for people who:

    • Are taking, or have recently taken, antibiotics

    • Have spent some time in a hospital or in a long-term care facility, such as a nursing home

    • Have a weakened immune system

    • Are 65 years of age or older

    When C. difficile germs take hold and multiply in the gut (intestines),

    they can wreak havoc.  This center of gut health is called the microbiome. When it gets out of balance your health is at risk, and infections like C. difficile can result. The most common symptoms—watery diarrhea, nausea, stomach pain or cramps—can last for days.  If not treated right away, C. difficile can lead to serious medical problems for the person who has it. A severe C. difficile infection can be fatal for certain people.

    Many people may not realize that getting a relapse of the infection is highly possible. This is called recurrent C. difficile.  Did you know? C. difficile is very contagious and can become a serious health threat to others in the home and the community.

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io